In today's Pharmaceutical Executive Daily, Cellenkos announces FDA clearance of its investigational new drug application for ...

FDA authorization supports a mid-stage clinical evaluation of CK0802 in steroid-refractory GVHD, where steroid nonresponse is ...

BioNTech reports its first quarter finical results, including losses and declining Covid-19 revenue as the company ...

Aradigm Health CEO Will Shrank discusses the shift in value-based care models for cell and gene therapies. While advances in ...

Deal terms include $2.0 billion upfront and up to $200 million milestone-based consideration, with closing anticipated in ...

In today's Pharmaceutical Executive Daily, UCB announces a definitive agreement to acquire Candid Therapeutics for up to $2.2 ...

Integrated operating frameworks are displacing fragmented vendor ecosystems, enabling faster launch readiness, omnichannel ...

Pharmaceutical Executive spoke with Aradigm Health CEO Will Shrank at the Asembia ASX26 Summit in Las Vegas. During the ...

DTP functions as an “affordability waterfall,” dynamically routing patients to MFN cash pricing, commercial insurance, or ...

Rare Pediatric Disease PRVs can accelerate FDA review timelines for another asset, and their resale market creates a tangible ...

In today's Pharmaceutical Executive Daily, we cover Sun Pharma's $11.75 billion acquisition of Organon and IMG Pharma's move ...

Shareholder approval positions Garijo to steer strategy toward operational rigor, portfolio discipline, and more consistent ...